NPI: 1780652016 · PLANTATION, FL 33322 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/11/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/11/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,471 | $349K |
| 2019 | 10,446 | $264K |
| 2020 | 16,359 | $2.06M |
| 2021 | 12,371 | $560K |
| 2022 | 9,543 | $813K |
| 2023 | 182 | $37K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 23,099 | 823 | $1.49M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 17,589 | 988 | $1.32M |
| J1270 | Injection, doxercalciferol, 1 mcg | 5,804 | 298 | $530K |
| A4657 | Syringe, with or without needle, each | 1,887 | 844 | $307K |
| J1756 | Injection, iron sucrose, 1 mg | 1,360 | 183 | $85K |
| 85041 | 1,086 | 636 | $66K | |
| 85048 | 999 | 579 | $64K | |
| 83550 | 907 | 520 | $54K | |
| 83540 | 907 | 520 | $54K | |
| 83970 | 765 | 298 | $51K | |
| 82728 | 775 | 444 | $43K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 127 | 52 | $9K |
| 82108 | 67 | 38 | $5K |